{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Esophageal+Carcinoma", "query": { "condition": "Locally Advanced Esophageal Carcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 112, "total_pages": 12, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+Esophageal+Carcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T01:45:26.656Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00004233", "title": "S9915 Triacetyluridine, Fluorouracil, and Leucovorin in Treating Patients With Unresectable, Locally Advanced, or Metastatic Cancer of the Esophagus or Stomach", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "triacetyluridine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2001-02", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2011-07-25", "last_synced_at": "2026-05-22T01:45:26.656Z", "location_count": 97, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004233" }, { "nct_id": "NCT00005638", "title": "Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-10", "completion_date": "2004-04", "has_results": false, "last_update_posted_date": "2013-06-19", "last_synced_at": "2026-05-22T01:45:26.656Z", "location_count": 2, "location_summary": "Los Angeles, California • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005638" }, { "nct_id": "NCT00368329", "title": "Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Neoplasms", "Carcinoma, Squamous Cell", "Adenocarcinoma", "Esophageal Cancer" ], "interventions": [ { "name": "Capecitabine (Xeloda)", "type": "DRUG" }, { "name": "[18-F] Fluorodeoxyglucose (FDG)", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2006-06", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2012-07-16", "last_synced_at": "2026-05-22T01:45:26.656Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00368329" }, { "nct_id": "NCT00848783", "title": "Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer", "Gastric Adenocarcinoma", "Esophageal Cancer" ], "interventions": [ { "name": "Irinotecan", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Floxuridine", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2008-05", "completion_date": "2012-09", "has_results": true, "last_update_posted_date": "2018-01-08", "last_synced_at": "2026-05-22T01:45:26.656Z", "location_count": 3, "location_summary": "Los Angeles, California • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00848783" }, { "nct_id": "NCT00253708", "title": "Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "management of therapy complications", "type": "PROCEDURE" }, { "name": "massage therapy", "type": "PROCEDURE" }, { "name": "pain therapy", "type": "PROCEDURE" }, { "name": "psychosocial assessment and care", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 39, "start_date": "2004-12-01", "completion_date": "2013-01-01", "has_results": true, "last_update_posted_date": "2017-08-07", "last_synced_at": "2026-05-22T01:45:26.656Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00253708" }, { "nct_id": "NCT00022139", "title": "Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2002-01", "completion_date": "2009-01", "has_results": false, "last_update_posted_date": "2016-12-07", "last_synced_at": "2026-05-22T01:45:26.656Z", "location_count": 35, "location_summary": "Chanute, Kansas • Dodge City, Kansas • El Dorado, Kansas + 22 more", "locations": [ { "city": "Chanute", "state": "Kansas" }, { "city": "Dodge City", "state": "Kansas" }, { "city": "El Dorado", "state": "Kansas" }, { "city": "Kingman", "state": "Kansas" }, { "city": "Liberal", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00022139" }, { "nct_id": "NCT04641871", "title": "Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Solid Tumor" ], "interventions": [ { "name": "Sym021", "type": "DRUG" }, { "name": "Sym022", "type": "DRUG" }, { "name": "Sym023", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Symphogen A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2020-10-12", "completion_date": "2024-06-03", "has_results": false, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-05-22T01:45:26.656Z", "location_count": 12, "location_summary": "Aurora, Colorado • Jacksonville, Florida • Tampa, Florida + 9 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04641871" }, { "nct_id": "NCT07218003", "title": "A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Cervical Cancer", "Head and Neck Squamous Cell Cancer", "Triple Negative Breast Cancer (TNBC)", "Urothelial Carcinoma Bladder", "Gastroesophageal Junction (GEJ) Adenocarcinoma", "Esophageal Squamous Cell Cancer", "Gastric Cancer", "Cancer", "Solid Tumors (Phase 1)" ], "interventions": [ { "name": "RNDO-564", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rondo Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2025-11-17", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-05-22T01:45:26.656Z", "location_count": 11, "location_summary": "San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07218003" }, { "nct_id": "NCT01705340", "title": "Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adenocarcinoma of the Gastroesophageal Junction", "HER2-positive Breast Cancer", "Male Breast Cancer", "Recurrent Breast Cancer", "Recurrent Esophageal Cancer", "Recurrent Gastric Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Gastric Cancer", "Stage IV Breast Cancer", "Stage IV Esophageal Cancer", "Stage IV Gastric Cancer" ], "interventions": [ { "name": "Akt inhibitor MK2206", "type": "DRUG" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2012-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-30", "last_synced_at": "2026-05-22T01:45:26.656Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01705340" }, { "nct_id": "NCT03783442", "title": "A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Esophageal Squamous Cell Carcinoma (ESCC)" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Tislelizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 649, "start_date": "2018-12-11", "completion_date": "2024-08-22", "has_results": true, "last_update_posted_date": "2025-07-29", "last_synced_at": "2026-05-22T01:45:26.656Z", "location_count": 2, "location_summary": "New Haven, Connecticut • The Woodlands, Texas", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03783442" } ] }